Welcome to our dedicated page for Butterfly Network news (Ticker: BFLY), a resource for investors and traders seeking the latest updates and insights on Butterfly Network stock.
Butterfly Network, Inc. (NYSE: BFLY) is a healthcare and digital health company focused on portable, semiconductor-based ultrasound technology and ultrasound software solutions. The Butterfly Network news feed on Stock Titan highlights company announcements that relate to its handheld ultrasound devices, Ultrasound-on-Chip™ semiconductor platform, enterprise software and AI initiatives.
Investors and healthcare professionals following BFLY news will see updates on financial results and guidance, such as quarterly earnings releases and preliminary revenue expectations furnished through press releases and 8-K filings. These items often include commentary on revenue growth, cash usage, chip development milestones and the progress of enterprise offerings like Compass™ and Compass AI™.
News coverage also features product and platform developments, including launches of new software capabilities such as Compass AI, announcements about AI-enabled clinical tools like Auto B-line Counter or a Gestational Age AI tool, and information about developer-focused initiatives like Butterfly Garden™ and the planned Beam Steering API. These stories provide insight into how Butterfly is expanding its imaging platform and exposing core capabilities to partners and developers.
Another recurring theme in Butterfly Network news is global health and clinical impact. Press releases describe programs in Sub-Saharan Africa involving handheld probes, training and AI tools for obstetric ultrasound, as well as clinical publications that examine how Butterfly’s devices and software can affect workflows, costs and provider economics in hospital systems.
In addition, the BFLY news stream includes capital markets and corporate updates, such as participation in healthcare investor conferences, executive appointments and SEC-reported events like the NYSE’s decision to delist Butterfly’s public warrants while leaving the common stock listing under BFLY unchanged. For readers tracking Butterfly Network, this page offers a consolidated view of operational, financial, technological and regulatory developments as they are publicly disclosed.
Butterfly Network (NYSE: BFLY) announced GovRAMP and TX-RAMP authorizations for its Butterfly iQ+/iQ3 probes and Compass AI™ cloud workflow, enabling sales to all state and local government agencies including Texas.
The solution completed a third-party assessment by A-LIGN and a GovRAMP PMO quality review; Butterfly is pursuing FedRAMP in 2026 and additional certifications.
Butterfly Network (NYSE: BFLY) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 at 8:00 AM ET.
Joseph DeVivo, President and CEO, and John Doherty, EVP and CFO, will host a pre-market conference call and webcast to discuss financial performance and operational progress. The live webcast will be archived and a telephone replay is available through March 5, 2026.
Butterfly Network (NYSE: BFLY) said it expects fourth-quarter 2025 revenue growth of at least 17% year-over-year. The company described momentum in its handheld ultrasound business and highlighted plans to expand co-development and chip licensing opportunities, calling 2026 a potential inflection year. Butterfly will present a business update at the 44th J.P. Morgan Healthcare Conference on January 15, 2026 at 9:00 AM PST. The company said audited fourth-quarter and full-year 2025 results and 2026 guidance are expected in late February 2026. A webcast of the JP Morgan presentation will be available for replay through February 15, 2026.
Butterfly Network (NYSE: BFLY) announced a planned Beam Steering API release expected in first half of 2026 to allow third-party developers in Butterfly Garden and Ultrasound-on-Chip co-development programs to access its electronically steered 3D imaging capabilities.
The API exposes software-defined beam steering features (including off-axis beam tilt up to 20 degrees) previously reserved for Butterfly apps and is built on a semiconductor CMUT array with approximately 9,000 elements. The SDK is expected to support a subset of presets across abdominal, cardiac, obstetric, musculoskeletal, vascular, and lung imaging. Availability and technical scope depend on ongoing development, regulatory considerations, and partner agreements.
Butterfly Network (NYSE: BFLY) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2026 at 9:00 AM PST. Company executives Joseph DeVivo, John Doherty, and Megan Carlson will host investor meetings and deliver the presentation.
A webcast will be posted in the company's Events & Presentations investor section and will be available for replay through February 15, 2026. Investors may schedule one-on-one meetings via company contacts or through J.P. Morgan representatives.
Butterfly Network (NYSE: BFLY) will participate at the 8th Annual Evercore Healthcare Conference in Coral Gables, FL on Tuesday, December 2, 2025. Joseph DeVivo, President, CEO & Chairman, and Megan Carlson, Senior VP & Interim CFO, will take part in a fireside chat at 1:20 PM ET and will host one-on-one investor meetings.
A live webcast of the fireside chat will be available in the Events & Presentations section of the Butterfly investor website and will be available for replay after the event. One-on-one meetings can be scheduled through Evercore representatives.
Butterfly Network (NYSE:BFLY) launched Compass AI on November 17, 2025 — an AI-powered enterprise platform to manage scalable, revenue-ready point-of-care ultrasound (POCUS) programs.
Key claims: documentation compliance up to 94% (vs ~15% for traditional workflows), up to 5x more revenue from the same clinical volume, and charting time cut by up to 25%. Features include ambient Documentation Agent, AI QA Agent, Program Dashboard, EHR/PACS/SSO integration and Fleet Visibility. Compass AI is available immediately for demonstrations.
Butterfly Network (NYSE: BFLY) reported Q3 2025 results with $21.5M revenue (5% YoY) and reaffirmed full-year revenue guidance of $91M–$95M. The company reduced quarterly cash burn to a record low of $3.9M and held $144.2M cash at quarter-end. GAAP gross margin swung to a (17.5%) loss due to a $17.4M inventory write-down while adjusted gross margin rose to 63.9%. Net loss widened to $34.0M and adjusted EBITDA loss improved slightly to $8.1M. Operational milestones included ISO 27001, a JAMA clinical validation, FDA-submitted gestational-age AI, third-party app launch in Butterfly Garden, and P5.1 chip completion.
Butterfly Network (NYSE: BFLY) said its CEO and interim CFO will participate at the UBS Global Healthcare Conference in Palm Beach, FL on Tuesday, November 11, 2025 at 5:00 pm ET.
Joseph DeVivo, President, CEO & Chairman and Megan Carlson, SVP & Interim CFO will take part in a fireside chat and host one-on-one investor meetings. A live webcast will be available in the Events & Presentations section of the Butterfly investor website and will be available for replay after the event. One-on-one meetings are scheduled through UBS representatives.
Butterfly Network (NYSE:BFLY) announced it achieved multiple information-security accreditations on October 27, 2025, reinforcing its global data-protection posture.
The company obtained ISO 27001, SOC-2 Type 2, C5 Germany, and the NHS DSPT certifications, and was assessed by third-party auditor A-LIGN. Management said these certifications support enterprise-grade, secure medical imaging for hospitals and health systems across the US, UK, EU, and international markets.
The release also reiterates prior milestones: a 2024 GovRAMP Snapshot (first in medical imaging) and ongoing pursuits of full GovRAMP authorization, TX-RAMP, FedRAMP, and HITRUST CSF r2.
FAQ
What is the current stock price of Butterfly Network (BFLY)?
What is the market cap of Butterfly Network (BFLY)?
